07:00 , Jul 14, 2014 |  BioCentury  |  Politics, Policy & Law

Letter to BioCentury: Per states rights

Expanded access to experimental medicines is a highly contentious issue - and for all the wrong reasons. The paper from the Goldwater Institute, "Everyone Deserves the Right to Try: Empowering the Terminally Ill to Take...
07:00 , May 5, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Other

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Other Prolapse Matrix metalloproteinase 9 (MMP9); fibulin 5 (FBLN5; DANCE; UP50) Mouse and patient studies suggest that MMP9 inhibitors could help prevent...
07:00 , Sep 29, 2008 |  BioCentury  |  Product Development

Venturing into ophthalmic space

Venturing into ophthalmic space Company Type Date Raised Description Alacrity Biosciences Debt 3/5/07 $8.5 Developing compounds to treat ocular surface diseases, glaucoma and retinal disease. Lead compound is ALTY-0501, a topical formulation of doxycycline that...
07:00 , Oct 15, 2007 |  BC Week In Review  |  Clinical News

ALTY-0501: Phase II data

In a double-blind Phase II trial in 160 patients, ALTY-0501 missed the primary endpoint of a significant reduction in central corneal damage compared with placebo following exposure to a controlled adverse environment. Compared with placebo,...
01:13 , Oct 10, 2007 |  BC Extra  |  Clinical News

Alacrity's ALTY-0501 misses dry eye endpoint

Alacrity (Laguna Hills, Calif.) said ALTY-0501 missed the primary endpoint of a significant reduction in central corneal damage compared with placebo following exposure to a controlled adverse environment in a Phase II trial to treat...
07:00 , Jul 16, 2007 |  BC Week In Review  |  Company News

Alacrity management update

Alacrity Biosciences Inc. , Laguna Hills, Calif.   Business: Ophthalmic   Hired: Karin Ludwig as CMO, formerly SVP of clinical research at Amicus Therapeutics Inc.  ...